GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Institutional Ownership

Resverlogix (TSX:RVX) Institutional Ownership : 0.01% (As of Jun. 11, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Resverlogix's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Resverlogix's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Resverlogix's Float Percentage Of Total Shares Outstanding is 0.00%.

Resverlogix Institutional Ownership Historical Data

The historical data trend for Resverlogix's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Institutional Ownership Chart

Resverlogix Historical Data

The historical data trend for Resverlogix can be seen below:

2020-07-31 2020-08-31 2020-09-30 2020-10-31 2020-11-30 2020-12-31 2021-01-31 2021-02-28 2021-03-31 2021-04-30
Institutional Ownership 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01

Resverlogix Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Resverlogix (TSX:RVX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Institutional Ownership
Comparable Companies
TSXV:SBM XCNQ:BETR TSX:ATE TSX:AEZS XCNQ:ASEP XCNQ:PREV TSXV:KNE XCNQ:MDMA XCNQ:PHRM XCNQ:BIOV OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
RVXCF:USA RFS:Germany
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Website
https://www.resverlogix.com
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Executives
Aaron Bradley Cann Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines